Related Experiment Video

Updated: Jul 7, 2026

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

[Efficiency of taliton in treatment of ischemic cardiomyopathy]

    Georgian Medical News
    |February 6, 2008
    PubMed

    Insights

    This study shows carvedilol (taliton) effectively treats ischemic cardiomyopathy by improving heart function and reducing ECG abnormalities. The drug demonstrated a good safety profile with no observed side effects over six months.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Ischemic cardiomyopathy is a significant cause of heart failure.
    • Beta-blockers are a cornerstone in managing heart conditions.

    Purpose of the Study:

    • To evaluate the efficacy and safety of carvedilol (taliton) in patients with ischemic cardiomyopathy.
    • To assess the impact of carvedilol on cardiac function and electrical activity.

    Main Methods:

    • An open-label trial involving 20 patients with ischemic cardiomyopathy.
    • Patients received carvedilol (taliton) alongside standard therapy.
    • Treatment duration was 6 months, with dose titration up to 25 mg twice daily.

    Main Results:

    • Carvedilol significantly improved ejection fraction.
    • Left ventricular dimensions and volumes were reduced.
    • 24-hour ECG monitoring showed a decrease in ST depression.
    • No adverse side effects were reported during the trial.

    Conclusions:

    • Carvedilol (taliton) is an effective and safe treatment option for patients with ischemic cardiomyopathy.
    • The drug positively impacts cardiac function and reduces ischemic events.

    More Related Videos

    Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

    Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

    Published on: May 26, 2023

    Related Concept Videos

    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
    Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

    Cardiomyopathy III: Hypertrophic Cardiomyopathy

    Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
    Myocarditis III: Medical Management01:14

    Myocarditis III: Medical Management

    Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
    Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

    Cardiopulmonary Resuscitation IV: Pharmacological Management

    Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...